TIMOROST EYE DROPS

Timolol Maleate + Latanoprost
5 mg/mL + 50 micrograms/mL | 2.5 mL
Sterile ophthalmic solution.

DOSAGE AND ADMINISTRATION

Adults, including elderly: Instil one drop into the affected eye(s) **once daily**, or as directed by the ophthalmologist. Do not exceed one drop in the affected eye(s) per day. If a dose is missed, continue with the next scheduled dose; do not double the dose. Monitor intraocular pressure as advised.

WARNINGS — OCULAR

Latanoprost may gradually increase brown iris pigmentation, potentially permanently, especially in mixed-colour irides. It may darken eyelid skin and alter eyelash length, thickness or direction. Use cautiously with history of herpetic keratitis, intraocular inflammation, aphakia/pseudophakia with disrupted posterior capsule or risk factors for macular oedema.

PAEDIATRIC USE

Safety and efficacy in children and adolescents have not been established. Use only if prescribed by a specialist.

OVERDOSAGE

Accidental ingestion or excessive instillation may cause systemic beta-blocker toxicity, including bradycardia, hypotension and bronchospasm. Seek urgent medical care. Treatment is supportive and symptom-directed.

COMPOSITION

Each 1 mL contains Timolol Maleate equivalent to Timolol 5 mg and Latanoprost 50 micrograms. Excipients and preservative: as per the approved Timorost formulation.

INSTRUCTIONS FOR USE

Wash hands before use. Tilt head back and gently pull down the lower eyelid. Instil one drop without touching the bottle tip to the eye, eyelids, fingers or other surfaces. Close eyelids or gently press the inner corner of the eye for 2 minutes to limit systemic absorption. Replace cap tightly. Separate other eye drops by at least 5 minutes.

PRECAUTIONS

Beta-blockers may mask hypoglycaemia and signs of hyperthyroidism; use caution in diabetes, thyroid disease, myasthenia gravis and patients with severe allergy or at risk of anaphylaxis. Tell the anaesthetist before surgery. Avoid simultaneous use of two ophthalmic beta-blockers or two prostaglandin analogues unless specifically directed.

ADVERSE REACTIONS

Ocular: irritation, stinging, redness, blurred vision, eye pain, dry eye, conjunctival hyperaemia, increased iris pigmentation and eyelash changes. Systemic: headache, dizziness, fatigue, slow heart rate, low blood pressure and breathing difficulty. Report severe or persistent effects promptly.

PRESENTATION

Timorost Eye Drops: sterile ophthalmic solution, 2.5 mL bottle.

PHARMACOLOGICAL CLASS

Antiglaucoma combination: non-selective beta-adrenoceptor antagonist (timolol) and prostaglandin F2-alpha analogue (latanoprost).

INDICATIONS

Reduction of elevated intraocular pressure in adults with open-angle glaucoma or ocular hypertension who respond inadequately to topical beta-blockers or prostaglandin analogues.

WARNINGS — CARDIORESPIRATORY

Ophthalmic timolol is systemically absorbed and may cause serious bronchospasm, bradycardia, hypotension or cardiac failure. Use with caution in patients with cardiovascular disease and assess pulmonary history. Seek urgent attention for wheezing, difficulty breathing, fainting, chest symptoms or very slow pulse.

DRUG INTERACTIONS

Systemic beta-blockers, calcium channel blockers (e.g., verapamil/diltiazem), digoxin, antiarrhythmics, guanethidine and catecholamine-depleting agents may increase risk of bradycardia or hypotension. CYP2D6 inhibitors may increase timolol effects. Additional prostaglandin analogues can paradoxically increase intraocular pressure.

STORAGE

Follow the locally approved Timorost storage and in-use conditions. Comparable latanoprost/timolol solutions commonly require refrigeration at 2–8°C before opening and storage below 25°C after opening, with disposal after 4 weeks; these conditions must be confirmed for Timorost before printing. Protect from light and keep out of reach of children.

PHARMACOLOGY

Latanoprost lowers intraocular pressure by increasing aqueous humour outflow, mainly via the uveoscleral pathway. Timolol lowers intraocular pressure by reducing aqueous humour production. The combination provides complementary intraocular pressure reduction.

CONTRAINDICATIONS

Hypersensitivity to timolol, latanoprost or product components; bronchial asthma or history of asthma; severe chronic obstructive pulmonary disease; sinus bradycardia, sick sinus syndrome, sinoatrial block, second- or third-degree atrioventricular block without pacemaker, overt cardiac failure or cardiogenic shock.

CONTACT LENSES

If the product contains benzalkonium chloride, remove soft contact lenses before instillation and wait at least 15 minutes before reinsertion. Confirm preservative and lens instructions against approved product information.

PREGNANCY AND LACTATION

Not recommended during pregnancy unless clearly necessary after specialist risk-benefit assessment. Timolol may cause fetal or neonatal beta-blockade; monitoring may be needed after late-pregnancy exposure. Timolol can enter breast milk; assess whether breastfeeding or treatment should continue. Avoid unsupervised use.

MANUFACTURED BY

Vega Pharmaceuticals (Pvt.) Ltd.